Gene and cell therapies advancing under tightening FDA guidance

This cluster tracks gene and cell therapies moving from concept to clinic, with CRISPR-based treatments targeting heart disease, dyslipidemia, neurodegeneration, rare childhood disorders, and inherited blindness. Regulators are both enabling and constraining progress: the FDA is lifting clinical holds on some CRISPR programs and sketching faster pathways for personalized therapies, while demanding new trials and more data for others. In parallel, companies and researchers are investing in better delivery systems (like lipid nanoparticles and liver-targeted editing), scalable and compliant manufacturing platforms, and even AI-assisted genetic engineering, signaling a push toward safer, one-time precision cures at industrial scale.